Bhutan Pure Origanic Cordyceps

2022 New Cordyceps Coming soon

Skip to main content
Department of Oncology
Search
Search
NewsAnti-cancer drug derived from fungus shows promise in clinical trials
Anti-cancer drug derived from fungus shows promise in clinical trials
Clinical Trials Research

7 October 2021

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana has found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

An image of the fungus Cordyceps sinensis. Cordycepin is derived from Cordyceps sinensis, which has been used in traditional Chinese medicine for hundreds of years to treat cancers and other inflammatory diseases. Thanks to this Oxford University-NuCana partnership, a new drug called NUC-7738 has been derived from Cordycepin and is now being tested in clinical trials.
Oxford University researchers have worked in collaboration with industry leaders NuCana to assess a novel chemotherapy drug derived from a fungus. A study in Clinical Cancer Research has shown that the new drug NUC-7738, developed by NuCana, has a up to 40 times greater potency for killing cancer cells than its parent compound, with limited toxic side effects.

The naturally-occurring nucleoside analogue known as Cordycepin (a.k.a 3’-deoxyadenosine) is found in the Himalayan fungus Cordyceps sinensis and has been used in traditional Chinese medicine for hundreds of years to treat cancers and other inflammatory diseases. However, it breaks down quickly in the blood stream, so a minimal amount of cancer-destroying drug is delivered to the tumour. In order to improve its potency and clinically assess its applications as a cancer drug, biopharmaceutical company NuCana has developed Cordycepin into a clinical therapy, using their novel ProTide technology, to create a chemotherapy drug with dramatically improved efficacy.

Once inside the body, Cordycepin requires transport into cancer cells by a nucleoside transporter (hENT1), it must be converted to the active anti-cancer metabolite, known as 3’-dATP, by a phosphorylating enzyme (ADK), and it is rapidly broken down in the blood by an enzyme called ADA. Together, these resistance mechanisms associated with transport, activation and breakdown result in insufficient delivery of anti-cancer metabolite to the tumour. NuCana have utilised novel ProTide technology to design a therapy that can bypass these resistance mechanisms and generate high levels of the active anti-cancer metabolite, 3’-dATP, inside cancer cells.

An image of the fungus Cordyceps sinensis. This fungus grows naturally on caterpillars at high altitudes in the Himalayas. Cordycepin is derived from Cordyceps sinensis, which has been used in traditional Chinese medicine for hundreds of years to treat cancers and other inflammatory diseases. Thanks to this Oxford University-NuCana partnership, a new drug called NUC-7738 has been derived from Cordycepin and is now being tested in clinical trials.
An image of the fungus Cordyceps sinensis. This fungus grows naturally on caterpillars at high altitudes in the Himalayas. Cordycepin is derived from Cordyceps sinensis, which has been used in traditional Chinese medicine for hundreds of years to treat cancers and other inflammatory diseases. Thanks to this Oxford University-NuCana partnership, a new drug called NUC-7738 has been derived from Cordycepin and is now being tested in clinical trials.

ProTide technology is a novel approach for delivering chemotherapy drugs into cancer cells. It works by attaching small chemical groups to nucleoside analogues like Cordycepin, which are then later metabolised once it has reached the patient’s cancer cells, releasing the activated drug. This technology has already been successfully used in the FDA approved antiviral drugs Remsidivir and Sofusbuvir to treat different viral infections such as Hepatitis C, Ebola and COVID-19.

The results of the study published in Clinical Cancer Research suggest that by overcoming key cancer resistance mechanisms, NUC-7738 has greater cytotoxic activity than Cordycepin against a range of cancer cells.

Oxford researchers and their collaborators in Edinburgh and Newcastle are now assessing NUC-7738 in the Phase 1 clinical trial NuTide:701, which tests the drug in patients with advanced solid tumours that were resistant to conventional treatment. Early results from the trial have shown that NUC-7738 is well tolerated by patients and shows encouraging signs of anti-cancer activity.



Cordyceps sinensis has had potential applications in cancer treatment for hundreds of years, but the limitations of its bioactive compound Cordycepin has prevented its development into approved chemotherapy drugs. The exciting development of NUC-7738 alongside NuCana using their ProTide technology has now overcome those limitations.

The story of NUC-7738 wonderfully demonstrates how a pharmaceutical company, scientists and doctors can combine their expertise to develop new cancer treatments for patients. This is bench-to-bedside medicine at its best!
- Lead researcher, Professor Sarah Blagden, from the University of Oxford, Department of Oncology

Further Phase 2 clinical trials of this drug are now being planned in partnership with NuCana, to add to growing number of ProTide technology cancer drugs that are being developed to treat cancer.

ABOUT THIS STUDY
This study was led by Prof Sarah Blagden and Dr Hagen Schwenzer, in partnership with NuCana via the Clinical Positioning Network: an Oxford Cancer service that partners commercial organisations with leading academics to clinical develop novel cancer diagnostics and therapeutics. Additional partners involved in this project include researchers at the Universities of St Andrew’s and Cardiff. NuCana in collaboration with a team in Cardiff University, synthesised the ProTide version of 3’-deoxyadenosine or Cordycepin called NUC-7738. ProTide technology was invented by NuCana's late Chief Scientific Officer, Professor Christopher McGuigan at Cardiff University. In vitro research was conducted at the Universities of Oxford and St Andrew’s. The clinical trial was led from the Oxford Early Phase Clinical Trials Unit, with additional recruitment in Edinburgh and Newcastle.

NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying ProTideTM technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogues, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and haematological tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilising their proprietary technology, NuCana are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells

SIMILAR STORIES
Oxford cancer clinical trials unit receives acclaimed nursing award
The nursing team at the Early Phase Clinical Trials Unit has been awarded the Excellence in Cancer Research Nursing Award 2021.

Oxford to assess revolutionary multi-cancer blood test in trial, for future implementation in the NHS
A partnership between the University of Oxford and GRAIL, LLC will evaluate the use of a new, non-invasive, multi-cancer early detection test known as Galleri in suspected cancer patients.

NCITA Publishes Comment Article in the British Journal of Cancer
University of Oxford Announces Opening of PanDox Phase 1 Study investigating Targeted Drug Delivery by Focused Ultrasound for Pancreatic Cancer
The University of Oxford is pleased to announce commencement of enrollment for the Phase I PanDox study of thermosensitive liposomal doxorubicin triggered by focused ultrasound in patients with pancreatic cancer.

Further funding secured to hunt out cancer using innovative radiotherapy techniques
Initial success leads to new award for Oxford researcher pushing forward new cancer-hunting radiotherapy despite lockdown.

Reprogramming tumour cells using an antimalarial drug
Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.

Accessibility Statement
Copyright Statement
Data Privacy Notice
Freedom of Information
Sitemap
Site Map
Accessibility
Cookies
Contact us
Log in
Intranet

HAPPY 10th ANNIVERSARY OF THE ROYAL WEDDING🙏🙏🙏

2021 Cordyceps Auction(Bumthang)

WHAT IS CORDYCEPS?
Cordyceps is a medicinal mushroom revered for its powerful adaptogenic qualities. In the Taoist tradition of herbal medicine Cordyceps is considered to be a life-enhancing herb. Used to increase blood oxygenation and cultivate Jing - the primordial energy that resides within the kidneys. When we increase our Jing, we improve our core energy and increase cellular performance and endurance. We reduce our recovery time after exertion and cultivate an overall robust feeling in the body, mind and spirit. Cordy is safe for use in both the young and young at heart.

https://youtu.be/uDHdN_rTQHQ

Magical caterpillar fungus from the Himalaya - Cordyceps sinensis Himalayan Gold – the mystery of Cordyceps sinensisIt's that time of year once more when the high altitude alpine meadows of the Himalaya get into spring-summ...

A stronger immune system, more energy, improved endurance, and better stamina … one ingredient promises all of that. Whether it’s as an extract, a pill, or powdered into your coffee, the cordyceps fungus is promoted as a one-stop-shop to cure what ails you. Known as Himalayan Gold because it is often farmed in the Himalayan plateaus, cordyceps has long been used in ancient Chinese and Tibetan medicine for curing diarrhea, headache, cough, rheumatism, liver disease, kidney disease, and much more.

Sexual problems that prevent satisfaction during s*xual activity. Early research shows that taking a specific cordyceps product (CordyMax Cs-4) daily for 40 days might improve s*x drive in people with low s*x drive.
Anemia.

Other Name(s): Caterpillar Fungus, Caterpillar Mushroom, Cs-4, Champignon Chenille, Chinese Caterpillar Fungus, Cordyceps sinensis, D**g Chong Xia Cao, D**g Chong Zia Cao, Hsia Ts'Ao Tung Ch'Ung, Ophiocordyceps sinensis, Tochukaso, Vegetable Caterpillar.july 24/07/2021

what is Cordyceps?
As we discussed in a previous episode, the cordyceps fungus grows like a parasite out of the brains of insects and spiders. The fungus takes over the bodies and brains of its victims forcing their zombified bodies to permanently relocate to the trees and low-lying jungle plants where the conditions are ideal for the fungus to thrive

Bhutan pure Origanic Cordyceps